Cervical Intraepithelial Neoplasia News and Research

RSS

Advaxis files investigational new drug application for Lovaxin C

Advaxis Inc. completed its filing of a new investigational new drug ("IND") application with the U.S. Food and Drug Administration ("FDA"). This filing follows the successful completion of a Phase I study overseas.

20 May 2008

GSK's Cervarix receives positive opinion in Europe

GlaxoSmithKline has announced that its cervical cancer candidate vaccine received a positive opinion from the European Committee for Human Medicinal Products (CHMP) for the prevention of precancerous lesions (high grade cervical intraepithelial neoplasia - CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus types 16 and 18.

19 Jul 2007

Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress.

18 Apr 2007

Roche and Transgene S.A. partner on HPV vaccine program

Roche and Transgene S.A. have announced that they have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from Transgene's therapeutic vaccine program against Human Papilloma Virus-mediated diseases.

11 Apr 2007

FDA accepts two Roche diagnostics HPV tests for review

Roche has announced today that the United States (U.S.) Food & Drug Administration has accepted for review its applications for two human papillomavirus (HPV) tests.

From Roche Sequencing and Life Science 6 Mar 2007

Human Papillomavirus testing and liquid-based cytology

Human papillomavirus (HPV) testing was more sensitive than traditional Pap smears at detecting precancerous lesions of the cervix, a study in the Journal of the National Cancer Institute reports.

7 Jun 2006

Studies show HPV testing is more sensitive than current screening methods

The current technique for screening for cervical cancer involves collecting cells by way of a pap smear and examining them under a microscope. Although this method has reduced cervical cancer in countries where it is regularly used, it has several weaknesses.

3 Apr 2006

Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia

Women who have had pre-cancerous cells removed remain at higher than average risk of developing cervical cancer in the 20 years following treatment, says research in the British Medical Journal (BMJ).

26 Nov 2005

A promising new vaccine against a pre-cancerous cervical virus

Updated data from a study on a promising new vaccine against a pre-cancerous cervical virus shows superior efficacy in preventing cervical pre-cancers and non-invasive cervical cancer

1 Nov 2005

New research into Human Papilloma Virus (HPV) and Cervical Cancer

Cervical cancer is the second-most prevalent cancer in women and, despite encouraging improvements in screening leading to earlier detection, cervical cancer still kills many women every year. The risk of cervical cancer is increased by infection with certain types of human papilloma virus (HPV).

12 Apr 2004